Business
DIAGNOS and ÉTS Announce $1M+ Federal Investment to Propel Next-Generation Retinal AI Innovation
BROSSARD, Quebec, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or th...
About this update from Diagnos Inc.
[{"type":"text","content":"DIAGNOS and ÉTS Announce $1M+ Federal Investment to Propel Next-Generation Retinal AI Innovation\nBROSSARD, Quebec, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a company dedicated to the early detection of critical eye-related health issues using advanced technology based on Artificial Intelligence (AI), and the École de technologie supérieure (ÉTS) today announced a major federal investment exceeding 1 Million $CAD to accelerate the development of next-generation artificial intelligence for retinal image analysis. The initiative underscores the strength of Canada’s research ecosystem and DIAGNOS’ strategy to advance clinically meaningful AI solutions for eye health. The project represents a robust, multi-year commitment from the Canadian innovation ecosystem, combining scientific excellence, talent development, and industry collaboration: Natural Sciences and Engineering Research Council of Canada (NSERC) has committed $725,734 over five years through its Alliance Grant program to support advanced research activities and core discovery costs.Mitacs will contribute $293,331 to fund specialized Accelerate internships, reinforcing industry–academic collaboration.Talent Development: The funding supports eight (8) Highly Qualified Personnel (HQPs)—including five graduate students and three postdoctoral researchers—who will develop state-of-the-art expertise and algorithms at the intersection of artificial intelligence and healthcare. DIAGNOS Contribution DIAGNOS is providing financial and in-kind contributions matching the NSERC-Mitacs Alliance grant, via the establishment of an industrial research Chair at the ÉTS. The company's financial contribution amounts to $500,000 over five years (equivalent to $100,000 per year), supporting the execution of the research program and reinforcing its long-term commitment to advancing next-generation retinal AI innovation. “This funding builds on our investment and experience, unlocking eight (8) additional resources that expand our research and development capacity,” said André Larente, President and CEO of DIAGNOS. “By combining federal investment with our internal expertise, proprietary dat...